{"id":"ccx-354-c","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4444976","moleculeType":"Small molecule","molecularWeight":"451.92"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CCR4 is expressed on T cells and other immune cells involved in inflammatory and allergic responses. By antagonizing CCR4, CCX-354-C prevents the migration of these cells to inflamed tissues, thereby reducing inflammation. This mechanism is being explored for autoimmune and inflammatory conditions.","oneSentence":"CCX-354-C is a C-C chemokine receptor 4 (CCR4) antagonist that blocks immune cell recruitment to reduce inflammatory responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:07:39.396Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune conditions (specific indication under investigation)"}]},"trialDetails":[{"nctId":"NCT01242917","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":159},{"nctId":"NCT01027728","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-12","conditions":"Rheumatoid Arthritis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CCX-354-C","genericName":"CCX-354-C","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CCX-354-C is a C-C chemokine receptor 4 (CCR4) antagonist that blocks immune cell recruitment to reduce inflammatory responses. Used for Inflammatory and autoimmune conditions (specific indication under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}